Patents by Inventor Larry Wheeler

Larry Wheeler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5561132
    Abstract: A method of treating a mammal comprising administering an effective amount of a compound of the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, is disclosed wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms wherein the desired therapeutic effect is an alteration in the rate of fluid transport in the gastrointestinal tract.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: October 1, 1996
    Assignee: Allergan
    Inventors: James A. Burke, Michael E. Garst, Larry A. Wheeler
  • Patent number: 5552403
    Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is independently selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide treatment for ischemia.
    Type: Grant
    Filed: October 31, 1994
    Date of Patent: September 3, 1996
    Assignee: Allergan
    Inventors: James A. Burke, Michael E. Garst, Larry A. Wheeler
  • Patent number: 5418234
    Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8-positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: May 23, 1995
    Assignee: Allergan, Inc.
    Inventors: Charles Gluchowski, Michael E. Garst, James A. Burke, Larry A. Wheeler, Michael E. Garst
  • Patent number: 5399573
    Abstract: Compounds of the formula: ##STR1## are useful for treatment of cataracts in mammals.
    Type: Grant
    Filed: September 1, 1992
    Date of Patent: March 21, 1995
    Assignee: Allergan, Inc.
    Inventors: William H. Garner, Larry A. Wheeler
  • Patent number: 5373010
    Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## , pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: December 13, 1994
    Assignee: Allergan, Inc.
    Inventors: Charles Gluchowski, Michael E. Garst, James A. Burke, Larry A. Wheeler
  • Patent number: 5326763
    Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a reduction inflammation in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.
    Type: Grant
    Filed: January 29, 1993
    Date of Patent: July 5, 1994
    Assignee: Allergan, Inc.
    Inventors: Charles Gluchowski, Michael E. Garst, James A. Burke, Larry A. Wheeler
  • Patent number: 5231096
    Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## ,pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.
    Type: Grant
    Filed: January 13, 1992
    Date of Patent: July 27, 1993
    Assignee: Allergan, Inc.
    Inventors: Charles Gluchowski, Michael E. Garst, James A. Burke, Larry A. Wheeler
  • Patent number: 4839385
    Abstract: Compounds derived form the marine sponge Laffariella variabilis and known by the name manoalide, and its derivatives, modify calcium homeostasis.
    Type: Grant
    Filed: August 25, 1987
    Date of Patent: June 13, 1989
    Assignees: The Regents of the University of California, Allergan, Inc.
    Inventors: Shmuel Maullem, George Sachs, Larry Wheeler
  • Patent number: 4786651
    Abstract: Manoalide and its derivatives are useful in the treatment of cutaneous hyperproliferative dermatoses.
    Type: Grant
    Filed: February 3, 1986
    Date of Patent: November 22, 1988
    Assignee: Allergan, Inc.
    Inventor: Larry Wheeler
  • Patent number: 4524063
    Abstract: A topical lodoxamide composition having enhanced efficacy for treatment of ocular allergic diseases. The composition comprises the addition of polyvinyl alcohol to an aqueous solution containing lodoxamide tromethamine.
    Type: Grant
    Filed: December 22, 1983
    Date of Patent: June 18, 1985
    Assignee: Allergan Pharmaceuticals, Inc.
    Inventor: Larry A. Wheeler